Delayed
Nasdaq Stockholm
04:32:38 16/05/2024 pm IST
|
5-day change
|
1st Jan Change
|
9.22
SEK
|
-2.95%
|
|
-7.34%
|
+15.25%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
305
|
281.1
|
496.5
|
415.2
|
927.8
|
927.8
|
-
|
Enterprise Value (EV)
1 |
196
|
248.9
|
347.1
|
291.8
|
621.1
|
833.8
|
876.2
|
P/E ratio
|
-3.13
x
|
-3.6
x
|
-4.58
x
|
-3.42
x
|
-5
x
|
-16.8
x
|
-21.3
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
18.1
x
|
11.3
x
|
15.7
x
|
7.29
x
|
6.97
x
|
7.27
x
|
5.42
x
|
EV / Revenue
|
11.6
x
|
10
x
|
10.9
x
|
5.12
x
|
5.54
x
|
6.54
x
|
5.12
x
|
EV / EBITDA
|
-2.47
x
|
-3.2
x
|
-4.37
x
|
-3.61
x
|
-8.54
x
|
-17.3
x
|
-22.2
x
|
EV / FCF
|
-2.26
x
|
-3.05
x
|
-3.87
x
|
-3.27
x
|
-6.6
x
|
-11.9
x
|
-26.8
x
|
FCF Yield
|
-44.3%
|
-32.8%
|
-25.8%
|
-30.5%
|
-15.1%
|
-8.4%
|
-3.73%
|
Price to Book
|
2.25
x
|
3.14
x
|
1.89
x
|
1.83
x
|
3.33
x
|
5.16
x
|
6.92
x
|
Nbr of stocks (in thousands)
|
17,733
|
17,733
|
57,075
|
71,343
|
97,659
|
97,659
|
-
|
Reference price
2 |
17.20
|
15.85
|
8.700
|
5.820
|
9.500
|
9.500
|
9.500
|
Announcement Date
|
13/02/20
|
11/02/21
|
22/02/22
|
21/02/23
|
06/02/24
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
16.87
|
24.87
|
31.73
|
56.98
|
112.2
|
127.6
|
171.3
|
EBITDA
1 |
-79.43
|
-77.72
|
-79.45
|
-80.85
|
-88.85
|
-48.33
|
-39.4
|
EBIT
1 |
-83.53
|
-84.3
|
-89.18
|
-90.57
|
-91.96
|
-54.47
|
-35.83
|
Operating Margin
|
-495.03%
|
-338.94%
|
-281.11%
|
-158.94%
|
-81.99%
|
-42.7%
|
-20.92%
|
Earnings before Tax (EBT)
1 |
-83.75
|
-84.54
|
-94.08
|
-99.63
|
-130.7
|
-55
|
-43.34
|
Net income
1 |
-84.24
|
-84.59
|
-93.92
|
-99.39
|
-130.5
|
-55.2
|
-43.77
|
Net margin
|
-499.29%
|
-340.1%
|
-296.03%
|
-174.41%
|
-116.35%
|
-43.27%
|
-25.55%
|
EPS
2 |
-5.500
|
-4.400
|
-1.900
|
-1.700
|
-1.600
|
-0.5650
|
-0.4467
|
Free Cash Flow
1 |
-86.82
|
-81.59
|
-89.69
|
-89.1
|
-94.03
|
-70
|
-32.67
|
FCF margin
|
-514.57%
|
-328.05%
|
-282.69%
|
-156.36%
|
-83.84%
|
-54.87%
|
-19.07%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
13/02/20
|
11/02/21
|
22/02/22
|
21/02/23
|
06/02/24
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
9.174
|
7.076
|
12.48
|
17.5
|
19.93
|
21.47
|
24
|
31.7
|
35
|
27.03
|
30
|
33.6
|
36.75
|
411
|
EBITDA
|
-21.87
|
-21.6
|
-21.53
|
-17.12
|
-20.51
|
-21.33
|
-17.59
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-24.26
|
-23.95
|
-23.98
|
-19.57
|
-22.89
|
-23.67
|
-19.92
|
-17.91
|
-29.1
|
-12.03
|
-14.35
|
-14.35
|
-14.95
|
-91
|
Operating Margin
|
-264.39%
|
-338.47%
|
-192.14%
|
-111.83%
|
-114.88%
|
-110.26%
|
-83.03%
|
-56.5%
|
-83.15%
|
-44.52%
|
-47.83%
|
-42.71%
|
-40.68%
|
-22.14%
|
Earnings before Tax (EBT)
1 |
-28.61
|
-24.08
|
-24.05
|
-19.68
|
-31.81
|
-
|
-20.07
|
-
|
-53.48
|
-11.28
|
-13.2
|
-13.4
|
-15.1
|
-
|
Net income
1 |
-28.73
|
-23.95
|
-23.93
|
-19.56
|
-31.95
|
-
|
-20.28
|
-
|
-53.84
|
-11.15
|
-14.45
|
-14.5
|
-15.1
|
-
|
Net margin
|
-313.12%
|
-338.51%
|
-191.71%
|
-111.77%
|
-160.31%
|
-
|
-84.49%
|
-
|
-153.84%
|
-41.24%
|
-48.17%
|
-43.15%
|
-41.09%
|
-
|
EPS
2 |
-
|
-0.4000
|
-0.4000
|
-0.3000
|
-
|
-
|
-
|
-
|
-
|
-0.1000
|
-0.1600
|
-0.1600
|
-0.1500
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
22/02/22
|
24/05/22
|
23/08/22
|
22/11/22
|
21/02/23
|
23/05/23
|
22/08/23
|
21/11/23
|
06/02/24
|
14/05/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
109
|
32.2
|
149
|
123
|
160
|
94
|
51.6
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-86.8
|
-81.6
|
-89.7
|
-89.1
|
-94
|
-70
|
-32.7
|
ROE (net income / shareholders' equity)
|
-92.2%
|
-68.4%
|
-50.1%
|
-40.6%
|
-41.1%
|
-26.1%
|
-23.1%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
7.630
|
5.060
|
4.600
|
3.180
|
2.410
|
1.840
|
1.370
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
-
|
2.5
|
0.06
|
0.13
|
0.08
|
1
|
1
|
Capex / Sales
|
-
|
10.04%
|
0.18%
|
0.23%
|
0.07%
|
0.78%
|
0.58%
|
Announcement Date
|
13/02/20
|
11/02/21
|
22/02/22
|
21/02/23
|
06/02/24
|
-
|
-
|
|
1st Jan change
|
Capi.
|
---|
| +15.25% | 86.84M | | +10.86% | 126B | | -5.75% | 11.27B | | +4.17% | 9.12B | | +40.13% | 5.61B | | -21.47% | 4.75B | | +8.77% | 3.45B | | -6.03% | 2.89B | | -12.05% | 2.07B | | -7.83% | 2.05B |
Medical Devices & Implants
|